%PDF-1.4
%
69 0 obj
<>
endobj
66 0 obj
<>
endobj
121 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-11-27T11:13:12Z
2024-03-29T00:06:47-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T00:06:47-07:00
application/pdf
Heather
2002-490.jan
uuid:9ac1982f-1dd1-11b2-0a00-6109275d6100
uuid:9ac19832-1dd1-11b2-0a00-aa0000000000
endstream
endobj
55 0 obj
<>
endobj
56 0 obj
<>
endobj
70 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 39 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 41 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 43 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 45 0 R/Type/Page>>
endobj
25 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 47 0 R/Type/Page>>
endobj
28 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 49 0 R/Type/Page>>
endobj
143 0 obj
[147 0 R]
endobj
144 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 61.6 714.5293 Tm
[(3.)-850.1 (Mahonen )54.8 (A, Pirskanen )54.8 (A, M\212enp\212\212 PH. Homologous and )]TJ
1.6 -1.25 Td
(heterologous regulation of 1,25-dihydroxyvitamin D3 receptor)Tj
0 -1.25 TD
[(mRNA)-220.2 (levels in human osteosarcoma cells. Biochim Biophys )54.8 (Acta)]TJ
0 Tc 0 Tw T*
[(1991;1088:1)36.9 (1)36.9 (1-8.)]TJ
-0.00011 Tc 0.02499 Tw -1.6 -1.25 Td
[(4.)-850.1 (Manolagas SC, )54.8 (Anderson DC, Lumb GA. Glucocorticoids regulate)]TJ
1.6 -1.25 Td
(the concentration of 1,25-dihydroxy vitamin D receptor in bone.)Tj
T*
(Nature 1979;227:314-5.)Tj
-1.6 -1.25 Td
[(5.)-850.1 (Manolagas SC, )17.7 (W)79.9 (einstein RS. New developments in the )]TJ
1.6 -1.25 Td
(pathogenesis and treatment of steroid-induced osteoporosis. J Bone)Tj
T*
(Miner Res 1999;14:1061-6.)Tj
-1.6 -1.25 Td
[(6.)-850.1 (McKenzie R, Reynolds JC, O\325Fallon )54.8 (A, et al. Decreased bone)]TJ
1.6 -1.25 Td
(mineral density during low dose glucocorticoid administration in a)Tj
T*
(randomized, placebo controlled trial. J Rheumatol 2000;27:2222-6.)Tj
-1.6 -1.25 Td
[(7.)-850.1 (Scudeletti M, Castagneta L, Imbimbo B, Puppo F)79.7 (, Pierre I, Indiveri)]TJ
1.6 -1.25 Td
[(F)79.8 (. New glucocorticoids. Mechanism of immunological activity at)]TJ
T*
[(the cellular level in the clinical setting. )54.8 (Ann NY)-183.3 (Acad Sci)]TJ
0 Tc 0 Tw T*
(1990;595:368-82.)Tj
-0.00011 Tc 0.02499 Tw -1.6 -1.25 Td
[(8.)-850.1 (Markham )54.8 (A, Bryson HM. Deflazacort. )54.8 (A)-220.1 (review of its )]TJ
1.6 -1.25 Td
[(pharmacological properties and therapeutic ef)17.7 (ficacy)64.8 (. Drugs)]TJ
0 Tc 0 Tw T*
(1995;50:317-33.)Tj
-0.00011 Tc 0.02499 Tw -1.6 -1.25 Td
[(9.)-850.1 (Genari C, Imbimbo B. Ef)17.7 (fects of prednisone and deflazacort on)]TJ
1.6 -1.25 Td
[(vertebral bone mass. Calcif )17.7 (T)35 (issue Int 1985;37:592-3.)]TJ
-2.1 -1.25 Td
[(10.)-850.1 (Ferraris JR, Pasqualini )17.7 (T)74 (, Legal S, et al. Ef)17.7 (fect of deflazacort versus)]TJ
2.1 -1.25 Td
(methylprednisone on growth, body composition, lipid profile, and)Tj
T*
[(bone mass after renal transplantation. )17.7 (The Deflazacort Study group.)]TJ
T*
(Pediatr Nephrol 2000;14:682-8.)Tj
-2.0631 -1.25 Td
[(1)36.8 (1)-0.1 (.)-850.1 (Canalis E, )54.8 (A)74 (violi L. Ef)17.7 (fects of deflazacort on aspects of bone)]TJ
2.0631 -1.25 Td
(formation in cultures of intact calvariae and osteoblast-enriched)Tj
T*
(cells. J Bone Miner Res 1992;7:1085-92.)Tj
-2.1 -1.25 Td
[(12.)-850.1 (Pereira RC, Durant D, Canalis E. )17.7 (T)35 (ranscriptional regulation of)]TJ
2.1 -1.25 Td
[(connective tissue growth factor by cortisol in osteoblasts. )54.8 (Am )]TJ
T*
(J Physiol Endocrinol Metab 2000;279:E570-6.)Tj
-2.1 -1.25 Td
[(13.)-850.1 (W)79.9 (alsh CA, Birch MA, Fraser )17.7 (WD, et al. Expression and secretion)]TJ
2.1 -1.25 Td
(of parathyroid hormone-related protein by human bone-derived)Tj
T*
[(cells in vitro: Ef)17.7 (fects of glucocorticoids. J Bone Miner Res)]TJ
0 Tc 0 Tw T*
(1995;10:17-25.)Tj
-0.00011 Tc 0.02499 Tw -2.1 -1.25 Td
[(14.)-850.1 (Borcsok I, Schairer HU, Sommer U, et al. Glucocorticoids regulate)]TJ
2.1 -1.25 Td
[(the expression of the human osteoblastic endothelium )54.8 (A)-220.1 (receptor)]TJ
0 Tc 33 46.25 Td
(gene. J Exp Med 1998;188:1563-73.)Tj
-0.00011 Tc -2.1 -1.25 Td
[(15.)-850.1 (V)110.8 (an Leeuwen JPTM, Birkenh\212ger JC, )17.7 (V)59.8 (ink-van )17.7 (W)39.9 (ijngaarden )17.7 (T)74 (,)]TJ
2.1 -1.25 Td
[(V)110.8 (an den Bemd GJCM, Pols HAP)110.7 (. Regulation of )]TJ
T*
(1,25-dihydroxyvitamin D receptor gene expression by parathyroid)Tj
T*
(hormone and cAMP-agonists. Biochem Biophys Res Commun)Tj
0 Tc 0 Tw T*
(1992;185:881-6.)Tj
-0.00011 Tc 0.02499 Tw -2.1 -1.25 Td
[(16.)-850.1 (Chomczynski P)110.7 (, Sacchi N. Single-step method of RNA)-220.2 (isolation by)]TJ
2.1 -1.25 Td
[(acid guanidinium thiocyanate-phenol-chloroform extraction. )54.8 (Anal)]TJ
T*
(Biochem 1987;162:156-9.)Tj
-2.1 -1.25 Td
[(17.)-850.1 (Chen )17.7 (TL, Hauschka PV)128.8 (, Feldman D. Dexamethasone increases)]TJ
2.1 -1.25 Td
(1,25-dihydroxyvitamin D receptor levels and augments )Tj
T*
(bioresponses in rat osteoblast-like cells. Endocrinology)Tj
0 Tc 0 Tw T*
[(1986;1)36.9 (18:1)36.9 (1)36.9 (19-26.)]TJ
-0.00011 Tc 0.02499 Tw -2.1 -1.25 Td
[(18.)-850.1 (Y)99.8 (ang-Y)99.8 (eng HS, Chambard JC, Sun )36.7 (YL, et al. )17.7 (T)35 (ranscriptional)]TJ
2.1 -1.25 Td
(interference between c-Jun and the glucocorticoid receptor: mutual)Tj
T*
[(inhibition of DNA)-220.2 (binding due to direct protein-protein interaction.)]TJ
T*
(Cell 1990;62:1205-15.)Tj
-2.1 -1.25 Td
[(19.)-850.1 (Hirst M, Feldman D. Glucocorticoid regulation of )]TJ
2.1 -1.25 Td
[(1,25-dihydroxyvitamin D receptors: diver)17.7 (gent ef)17.7 (fects on mouse and)]TJ
T*
[(rat intestine. Endocrinology 1982;1)36.8 (1)36.8 (1:1400-2.)]TJ
-2.1 -1.25 Td
[(20.)-850.1 (Lukert BP)110.7 (, Raisz LG. Glucocorticoid-induced osteoporosis:)]TJ
2.1 -1.25 Td
[(Pathogenesis and management. )54.8 (Ann Intern Med 1990;1)36.8 (12:352-64.)]TJ
-2.1 -1.25 Td
[(21.)-850.1 (Nielsen HK. Circadian changes in osteoblastic activity assessed by)]TJ
2.1 -1.25 Td
(serum osteocalcin. Physiological and methodological aspects. Dan)Tj
0 Tc T*
(Med Bull 1994;41:216-27.)Tj
-0.00011 Tc -2.1 -1.25 Td
[(22.)-850.1 (Feldman D, McCain )17.7 (T)79.9 (A, Hirst MA, Chen )17.7 (TL, Colston KW)91.7 (.)]TJ
2.1 -1.25 Td
[(Characterization of a cytoplasmic receptor)19.7 (-like binder for 1)]TJ
T*
(alpha,25 dihydroxycholecalciferol in rat intestinal mucosa. J Biol)Tj
0 Tc T*
(Chem 1979;254:10378-84.)Tj
-0.00011 Tc -2.1 -1.25 Td
[(23.)-850.1 (Komm BS, )17.7 (T)69.9 (erpening CM, Benz DJ, et al. Estrogen binding,)]TJ
2.1 -1.25 Td
(receptor mRNA, and biologic response in osteoblast-like )Tj
T*
(osteosarcoma cells. Science 1988;241:81-4.)Tj
-2.1 -1.25 Td
[(24.)-850.1 (Issa LL, Leong GM, Barry JB, Sutherland RL, Eisman JA.)]TJ
2.1 -1.25 Td
[(Glucocorticoid receptor)19.7 (-interacting protein-1 and )]TJ
T*
[(receptor)19.7 (-associated coactivator)19.7 (-3 dif)17.7 (ferentially interact with the)]TJ
T*
[(vitamin D receptor \(VDR\) and regulate )17.7 (VDR-retinoid X receptor)]TJ
T*
(transcriptional cross-talk. Endocrinology 2001;142:1606-15.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_1 1 Tf
8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2004; 31:1)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(172)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.09 396.47 -10.83 re
f*
0.5 w
109.25 59.09 396.47 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_2 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
49 0 obj
<>stream
8;Z\7lYc,5%*SO_?s`"eL"Hk_P]icc2W9)<=Q]mPMp^;j%Xo5@\T@:TJ*sSDXb9T*m2Tf5;PU21C@TFp&aE\LV04>))qpU+CL]Q&(0q7g>F]sS
b`N<(lAUC-r?Tr74*E;FOXt6$^4A*2qj>s+Eat`\lA=(6_g8@Q%tuL!s#pf/b&=i<
SoHggDnqO9?@Du^c0,hIl%.3.ZiQLg2!/)u
YT@Z+;C'd:Kk0[m9WR;4$,^jPK/0)-Fo:$9*dZeO[YGm^PWj2h\6F.F+rW]B:=eMU
8LSV-KVe=[h!Tp(AhSKpAJtbmr)l"i*f?,KPbT1&?!*#c"$;+S)+o*K1i:Y6gfP9K
>#XYoC=>uu&UA>#[]rGn?8VYG$mSYRbtZ[5S1@Sl9r>7g,IpD):3hdp=Dg7hpB=ri
P<@>8>Ql&$,b,kM+9>.*VMR&c0[$H?[g?<<p5f^_`Rm-HV16T[Xf2m;Oqij:X$Los)>_ha0:h%U>lg4^>ep/;diM5.D@s^
_83t(_83t(_8-N3HYa"oLq)bmn(@K/l_h>n2#[pabshO+~>
endstream
endobj
53 0 obj
[/Indexed/DeviceRGB 255 52 0 R]
endobj
52 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
77 0 obj
<>
endobj
72 0 obj
<>
endobj
108 0 obj
<>
endobj
126 0 obj
<>
endobj
73 0 obj
<>
endobj
100 0 obj
<>stream
HiPSYBPl Q{
EDZFFDE6%
QB K!,!H YȢ@"8n4j0cOkPtD/S_nտnsϩ?Uwqqzg{}\CxIL?}|'Ym8*cDžh3#W3b̘q2A;/&c+ҏjfV3&%F8&7ww](?i߫Jcy!X=qBQP#ŻѴORVLxb(pc/ch(&'ҁdD£}v1"oŊ'OGe
3ű+O̱F4q09UbMc= 1#1ao07-[~qҍ,beDLM/.s]o9\f]+W988+WvsG,6ZX*̬Vϭ](f*Uyflع=?j_o{1å.4Q>xGمT5~Zpx~W'j*iB"Nv@6G_6!5F^V5>Ayh-2ElssFo